- Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
- Transactions in Connection with Share Buy-back Program
- Genmab Announces Financial Results for the First Quarter of 2024
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
- Transactions in Connection with Share Buy-back Program Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Completion of share buy-back program
- Genmab Announces Initiation of Share Buy-Back Program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
More ▼
Key statistics
As of last trade, Genmab A/S (GE9:FRA) traded at 273.00, 10.66% above the 52 week low of 246.70 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 273.00 |
---|---|
High | 273.00 |
Low | 273.00 |
Bid | 273.30 |
Offer | 274.50 |
Previous close | 272.00 |
Average volume | 55.44 |
---|---|
Shares outstanding | 66.12m |
Free float | 66.12m |
P/E (TTM) | 24.19 |
Market cap | 132.44bn DKK |
EPS (TTM) | 82.80 DKK |
Data delayed at least 15 minutes, as of May 17 2024 08:16 BST.
More ▼